Silgan Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $6.7B+14.1% YoYTTM through 30 Jun 2026
Net Income $270.3M-2.2% YoYTTM through 30 Jun 2026
Free Cash Flow $342.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 17.7% |
| EBITDA Margin | 10.8% |
| Operating Margin | 9.2% |
| Net Margin | 4.1% |
Returns
12.7%ROE
3.1%ROA
3.9%ROIC
Balance Sheet Health
Debt / Equity1.91x
Current Ratio1.22x
Net Debt$3.3B
Cash & Equivalents$351.5M
Quality Metrics
Altman Z-Score1.79
Piotroski F-Score7 / 9
FCF Margin5.1%
Rule of 408.0
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $6.5B
Diluted EPS$2.55TTMFY2025: $2.70
Dividend
$0.42Per share, FY20261.12%Yield-5.6%5-yr growth
Capital Allocation
Capex Intensity4.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Dispensing and Specialty Closures | $2.7B | ||
| Metal Containers | $3.1B | ||
| Custom Containers | $637.6M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.